Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]

NCT01696240 Phase 3 UNKNOWN

The investigators hypothesized that udenafil, a newly developed phosphodiesterase type 5 inhibitor, would improve symptom, exercise capacity and hemodynamic status in patients with mild pulmonary hypertension.

Details

Lead sponsor	Seoul National University Hospital
Phase	Phase 3
Status	UNKNOWN
Enrolment	40
Start date	2012-09
Completion	2013-12

Conditions

• Mild Pulmonary Hypertension

Interventions

• Placebo
• Udenafil (Zydena)

Primary outcomes

• Change of maximal VO2 in cardiopulmonary exercise test — Baseline and 12th weeks
  Comparison between groups and within groups.

Countries

South Korea